

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims

Claim 1 (original): A method of enhancing pericyte cell proliferation comprising administering to a subject in need thereof an amount of a BPI protein product effective to enhance proliferation of pericyte cells.

Claim 2 (original): The method of claim 1 wherein the onset of diabetic retinopathy is prevented.

Claim 3 (currently amended): The method of claim 1 wherein the subject is suffering from a complication of diabetes selected from the group consisting of **diabetic retinopathy**, diabetic polyneuropathy, diabetic nephropathy, skeletal muscle degeneration after pericyte degeneration, and other organ complications of diabetes.

Claim 4 (original): The method of claim 1 wherein the subject is suffering from a disease associated with the presence of autoantibodies to pericytes.

Claim 5 (original): The method of claim 1 wherein the subject is suffering from age-related macular degeneration (ARMD).

Claim 6 (original): The method of claim 1 wherein the subject is suffering from ovarian failure.

Claim 7 (original): The method of claim 1 wherein the subject is suffering from multiple sclerosis.

Claim 8 (original): The method of claim 1 wherein the subject is suffering from Alzheimer's disease, or traumatic brain injury, or other conditions involving perturbation of the blood-brain-barrier, or partial seizures.

Claim 9 (original): The method of claim 1 wherein the subject is pregnant and placental development is enhanced.

Claim 10 (original): The method of claim 1 wherein the subject is in need of wound healing, and the BPI protein product is administered in an amount and under conditions effective to enhance production of fibroblasts.

Claim 11 (original): The method of claim 1 wherein the subject is suffering from a bone degenerative disorder, and the BPI protein product is administered in an amount and under conditions effective to enhance production of chondroblasts or osteoblasts.

Claim 12 (original): A method of inhibiting pericyte cell proliferation comprising administering to a subject in need thereof an effective amount of an agent that inhibits BPI protein product-induced proliferation of pericyte cells.

Claim 13 (original): The method of claim 12 wherein the subject is suffering from hypertension.

Claim 14 (original): The method of claim 12 wherein the subject is suffering from a disorder associated with vascular disease selected from the group consisting of formation of vascular calcifications and atherosclerotic plaques, atherosclerosis, restenosis, cerebrovascular ischemia, stroke, coronary artery disease, myocardial ischemia, myocardial infarction, peripheral vascular disease, Raynaud's syndrome, early occlusion of peripheral arteries and vascular remodeling associated with pulmonary hypertension.

Claim 15 (original): The method of claim 12 wherein the subject is suffering from acute respiratory distress syndrome (ARDS).

Claim 16 (original): The method of claim 12 wherein the subject is suffering from endometriosis or adenomyosis.

Claim 17 (original): A method of enhancing retinal epithelial cell proliferation comprising administering to a subject in need thereof an amount of a BPI protein product effective to enhance proliferation of retinal epithelial cells.

Claim 18 (original): The method of claim 17 wherein the subject is suffering from retinitis pigmentosa.

Claim 19 (original): The method of claim 17 wherein the subject is suffering from age-related macular degeneration.

Claim 20 (original): The method of claim 1 wherein the BPI protein product is an amino-terminal fragment of BPI protein having a molecular weight of about 20 kD to 25 kD, or a dimeric form thereof.

Claim 21 (original): The method of claim 1 wherein the BPI protein product is a BPI-derived peptide.

Claim 22 (original): The method of claim 21 wherein the BPI-derived peptide is XMP.679.

Claim 23 (original): A method of screening for a candidate inhibitor of BPI-induced proliferation of pericytes comprising the steps of:

- (a) detecting proliferation of pericytes in the presence of BPI protein product and in the presence and absence of a test compound; and
- (b) identifying said test compound as a candidate inhibitor of BPI-induced proliferation when proliferation of the pericytes is reduced in the presence of the test compound.

Claim 24 (original): A method of screening a BPI protein product for the ability to enhance proliferation of pericytes comprising the steps of:

- (a) detecting proliferation of pericytes in the presence and absence of a BPI protein product; and
- (b) identifying a BPI protein product as a candidate enhancer of pericyte proliferation when proliferation of the pericytes is increased in the presence of the BPI protein product.

Claim 25 (original): A method of screening for a candidate enhancer of pericyte proliferation comprising the steps of:

- (a) measuring proliferation of pericytes in the presence and absence of a test compound;
- (b) measuring proliferation of pericytes in the presence of said test compound and a BPI protein product, said BPI protein product at a concentration effective to enhance pericyte proliferation; and
- (c) identifying said test compound as a candidate enhancer of pericyte proliferation when pericyte proliferation is increased in step (a) but not further increased in step (b).

Claim 26 (original): A method of screening for a candidate enhancer of pericyte proliferation comprising the steps of:

- (a) measuring proliferation of pericytes in the presence and absence of a test compound;
- (b) measuring proliferation of pericytes in the presence of said test compound and a BPI protein product, said BPI protein product at a concentration effective to enhance pericyte proliferation; and
- (c) identifying said test compound as a candidate enhancer of pericyte proliferation when the increase in pericyte proliferation measured in step (a) is about the same as or less than the increase in pericyte proliferation measured in step (b).

Claim 27 (original): A method of enhancing epithelial cell proliferation comprising administering to a subject in need thereof an amount of a BPI protein product effective to enhance proliferation of epithelial cells.

Claim 28 (original): The method of claim 27 wherein the subject is suffering from retinitis pigmentosa or age-related macular degeneration.

Claim 29 (original): A method of screening for a candidate inhibitor of BPI-induced proliferation of epithelial cells comprising the steps of:

- (a) detecting proliferation of epithelial cells in the presence of BPI protein product and in the presence and absence of a test compound; and
- (b) identifying said test compound as a candidate inhibitor of BPI-induced proliferation when proliferation of the epithelial cells is reduced in the presence of the test compound.

Claim 30 (original): A method of screening a BPI protein product for the ability to enhance proliferation of epithelial cells comprising the steps of:

- (a) detecting proliferation of epithelial cells in the presence and absence of a BPI protein product; and
- (b) identifying a BPI protein product as a candidate enhancer of epithelial cell proliferation when proliferation of the epithelial cells is increased in the presence of the BPI protein product.

Claim 31 (original): A method of screening for a candidate enhancer of epithelial cell proliferation comprising the steps of:

- (a) measuring proliferation of epithelial cells in the presence and absence of a test compound;
- (b) measuring proliferation of epithelial cells in the presence of said test compound and a BPI protein product, said BPI protein product at a concentration effective to enhance epithelial cell proliferation; and
- (c) identifying said test compound as a candidate enhancer of epithelial cell proliferation when epithelial cell proliferation is increased in step (a) but not further increased in step (b).

Claim 32 (original): The method of any one of claims 23, 24, 25, 26, 29, 30 or 31 wherein proliferation is determined by the measuring the amount of MAP kinase phosphorylation.

Claim 33 (original): A method of enhancing pericyte proliferation in a subject with diabetes-induced retinal vascular permeability comprising administering to the subject an amount of a BPI protein product effective to enhance proliferation of pericytes.

Claim 34 (original): The method of claim 33 wherein the diabetes-induced retinal vascular permeability is reduced.

Claim 35 (original): A method of enhancing pericyte proliferation in a subject suffering from a pericyte degeneration disorder that is complications of diabetes, diseases associated with the presence of autoantibodies to pericytes, age-related macular degeneration (ARMD), ovarian failure, multiple sclerosis, Alzheimer's disease, traumatic brain injury, a condition involving perturbation of the blood-brain-barrier, partial seizures, or and placental development in pregnancy, comprising administering to the subject an amount of a BPI protein product effective to enhance proliferation of pericytes.

Claim 36 (original): A method of enhancing cell proliferation in a subject in need of wound healing, comprising administering to the subject an amount of a BPI protein product effective to enhance production of fibroblasts cells.

Claim 37 (original): A method of enhancing cell proliferation in a subject suffering from a bone degenerative disorder, comprising administering to the subject an amount of a BPI protein product effective to enhance production of chondroblasts or osteoblasts.

Claim 38 (original): A method for reducing pericyte proliferation in a subject suffering from a condition where pericyte proliferation is deleterious, that is hypertension, vascular calcifications, atherosclerotic plaques, atherosclerosis, restenosis, cerebrovascular ischemia, stroke, coronary artery disease, myocardial ischemia, myocardial infarction, peripheral vascular disease, Raynaud's syndrome, early occlusion of peripheral arteries and vascular remodeling associated with pulmonary hypertension, acute respiratory distress syndrome (ARDS), endometriosis or adenomyosis, comprising administering to the subject an amount of an agent that inhibits BPI protein product-induced proliferation of pericyte cells.

Claim 39 (original): A method for enhancing cell proliferation in a subject suffering from a retinal epithelial degeneration disorder that is retinitis pigmentosa or age-related macular degeneration, comprising administering to the subject an amount of a BPI protein product effective to enhance proliferation of retinal epithelial cells.